Profile data is unavailable for this security.
About the company
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
- Revenue in USD (TTM)0.00
- Net income in USD-86.76m
- Incorporated2012
- Employees20.00
- LocationRelmada Therapeutics Inc2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES 33134United StatesUSA
- Phone+1 (646) 876-3459
- Websitehttps://www.relmada.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coherus Biosciences Inc | 304.34m | -450.00k | 93.90m | 235.00 | -- | -- | 19.34 | 0.3085 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Oramed Pharmaceuticals, Inc. | 0.00 | 20.86m | 94.18m | 15.00 | 4.62 | 0.530 | 4.49 | -- | 0.4999 | 0.4999 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | 12.19 | -- | 12.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Cidara Therapeutics Inc | 31.58m | -116.17m | 95.02m | 69.00 | -- | 0.4711 | -- | 3.01 | -25.49 | -25.30 | 6.95 | 28.66 | 0.2617 | -- | 8.06 | 457,623.20 | -96.27 | -65.23 | -136.45 | -154.37 | 91.14 | -- | -367.91 | -100.61 | -- | -- | 0.0053 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Hillevax Inc | 0.00 | -156.27m | 95.09m | 90.00 | -- | 0.4594 | -- | -- | -3.38 | -3.38 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -55.47 | -- | -63.02 | -- | -- | -- | -- | -- | -- | -- | 0.1113 | -- | -- | -- | 22.68 | -- | -- | -- |
| Ikena Oncology Inc | 1.84m | -66.71m | 96.14m | 18.00 | -- | 0.5945 | -- | 52.14 | -1.43 | -1.43 | 0.0393 | 2.96 | 0.0112 | -- | -- | 42,883.72 | -40.52 | -29.72 | -43.17 | -34.62 | -- | -- | -3,617.57 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Regulus Therapeutics Inc | 0.00 | -35.39m | 96.23m | 31.00 | -- | 0.9802 | -- | -- | -1.26 | -1.26 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -47.90 | -53.74 | -52.71 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Relmada Therapeutics Inc | 0.00 | -86.76m | 98.97m | 20.00 | -- | 1.61 | -- | -- | -2.88 | -2.88 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -89.88 | -- | -100.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| MDxHealth SA | 80.74m | -40.80m | 100.48m | 300.00 | -- | -- | -- | 1.24 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Werewolf Therapeutics Inc | 9.28m | -53.73m | 100.51m | 45.00 | -- | 0.9663 | -- | 10.83 | -1.35 | -1.35 | 0.236 | 2.38 | 0.0548 | -- | 2.48 | 197,510.60 | -31.70 | -- | -34.39 | -- | -- | -- | -578.80 | -- | -- | -- | 0.1948 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -120.43m | 100.87m | 122.00 | -- | 0.9236 | -- | -- | -3.12 | -3.12 | 0.00 | 3.13 | 0.00 | -- | -- | 0.00 | -69.23 | -46.30 | -75.81 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Genelux Corp | 8.00k | -26.54m | 101.19m | 23.00 | -- | 2.65 | -- | 12,648.62 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Bioatla Inc | 0.00 | -104.56m | 101.51m | 65.00 | -- | 3.24 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Renovaro Inc | 0.00 | -80.65m | 102.53m | 25.00 | -- | 0.7447 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.8513 | 0.00 | -- | -- | 0.00 | -72.84 | -39.86 | -89.56 | -42.11 | -- | -- | -- | -- | -- | -10.76 | 0.0182 | -- | -- | -- | -103.23 | -- | -37.12 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 102.91m | 9.00 | -- | 17.32 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
| CervoMed Inc | 9.65m | -5.04m | 103.50m | 8.00 | -- | 2.07 | -- | 10.72 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Cue Biopharma Inc | 8.30m | -46.96m | 103.56m | 53.00 | -- | 3.87 | -- | 12.48 | -0.9743 | -0.9743 | 0.1718 | 0.4445 | 0.1437 | -- | 5.56 | 156,528.30 | -81.32 | -57.45 | -113.52 | -68.41 | -- | -- | -566.02 | -810.87 | -- | -- | 0.2242 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
Data as of Nov 11 2024. Currency figures normalised to Relmada Therapeutics Inc's reporting currency: US Dollar USD
30.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.25m | 4.13% |
| Deep Track Capital LPas of 30 Jun 2024 | 1.23m | 4.09% |
| Vestal Point Capital LPas of 30 Jun 2024 | 1.20m | 3.98% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 1.19m | 3.96% |
| Franklin Advisers, Inc.as of 30 Jun 2024 | 1.01m | 3.36% |
| Parsons Capital Management, Inc.as of 30 Sep 2024 | 1.00m | 3.32% |
| Palo Alto Investors LPas of 30 Jun 2024 | 732.40k | 2.43% |
| Opaleye Management, Inc.as of 30 Jun 2024 | 600.00k | 1.99% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 561.83k | 1.86% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2024 | 315.06k | 1.04% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
